

BEST AVAILABLE COPY

IAPI3 Rec'd PCT/PTO 16 JAN. 2007

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE
ACTING AS THE DESIGNATED/ELECTED OFFICE

In re: Patent application of John D. LAMBRIS

U.S. Appl. No. 10/528,496

I.A. Appl. No.: PCT/US03/29653

I.A. Filing Date: 22 September 2003 (22.09.2003)

Confirmation No.: 4405

For: COMPSTATIN ANALOGS WITH
IMPROVED ACTIVITY

Mail Stop PCT
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

RECEIVED
23 JAN 2007
Legal Staff
International Division

**PETITION UNDER 37 C.F.R. §1.181(a) REQUESTING
WITHDRAWAL OF HOLDING OF ABANDONMENT**

A Notification of Abandonment (PCT/DO/EO/909) was mailed by the United States Patent and Trademark Office in its capacity as a Designated/Elected Office on November 24, 2006 in connection with the above-identified application. The Notification of Abandonment indicated that the application was abandoned for failure to respond to the Notification of Missing Requirements (Form PCT/DO/EO/922) mailed July 5, 2006, within the time period set therein. It is respectfully submitted that the Notification of Abandonment is in error and should be withdrawn, for the reasons set forth below.

The U.S. Patent and Trademark Office in its capacity as a Designated/Elected Office mailed a NOTIFICATION TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE AND/OR AMINO ACID SEQUENCE DISCLOSURES (PCT/DO/EO/922) on July 5, 2006. A shortened statutory period for reply was set at two months after the date of mailing of the Notification, or by September 5, 2006.

Extensions of time are available under the provisions of 37 CFR 1.136(a), as set forth on the Notification. Thus, the final date on which a response may be filed in response to the Notification is February 5, 2007.

CERTIFICATE OF MAILING	
Date of Deposit:	January 12, 2007
I HEREBY CERTIFY THAT THIS PAPER IS BEING DEPOSITED WITH THE UNITED STATES POSTAL SERVICE AS FIRST CLASS MAIL, POSTAGE PREPAID, ON THE DATE INDICATED ABOVE AND IS ADDRESSED TO: Mail Stop PCT, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450	
Signature of person mailing page:	
JANET E. REFO, REG. NO. 36,252	
Type or print name of person	

PHIP531575\1


In support of this petition, Applicants hereby submit the following documents:

1. copy of Notification of Abandonment;
2. copy of Applicant's Amendment and Response to NOTIFICATION TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE AND/OR AMINO ACID SEQUENCE DISCLOSURES (PCT/DO/EO/922) submitted December 4, 2006 and accompanied by a Petition for three (3) month extension of time and the requisite fee, all mailed by U.S. Express Mail (copy of date-stamped Express Mail receipt enclosed); and
3. copy of return postcard from the U.S. Patent and Trademark Office for the documents listed above, date-stamped December 4, 2006.

It is respectfully submitted that no fee for this petition is due, because the application is not in fact abandoned (MPEP §711.03). However, the Commissioner is hereby authorized to charge any fees in connection with the petition to Deposit Account No. 50-0573.

Acknowledgment that this petition has been granted and that the application has been restored to pending status are respectfully requested.

Respectfully submitted,


BY _____
JANET E. REED
Registration No. 36,252
Drinker Biddle & Reath LLP
One Logan Square
18th and Cherry Streets
Philadelphia, PA 19103-6996
TEL: (215) 988-3111
FAX: (215) 988-2757
Attorney for Applicant



UNITED STATES PATENT AND TRADEMARK OFFICE

46483-0001(229798)
 UNITED STATES DEPARTMENT OF COMMERCE
 United States Patent and Trademark Office
 Address: COMMISSIONER FOR PATENTS
 P.O. Box 1450
 Alexandria, Virginia 22313-1450
 www.uspto.gov

U.S. APPLICATION NUMBER NO. 10/528,496	FIRST NAMED APPLICANT John D Lambris	ATTY. DOCKET NO. UPN-4470 / P2942
---	---	--------------------------------------

INTERNATIONAL APPLICATION NO. PCT/US03/29653	
I.A. FILING DATE 09/22/2003	PRIORITY DATE 09/20/2002

23973
 DRINKER BIDDLE & REATH
 ATTN: INTELLECTUAL PROPERTY GROUP
 ONE LOGAN SQUARE
 18TH AND CHERRY STREETS
 PHILADELPHIA, PA 19103-6996

CONFIRMATION NO. 4405

371
 ABANDONMENT/TERMINATION
 LETTER



OC000000021351777

Date Mailed: 11/24/2006

NOTIFICATION OF ABANDONMENT

The United States Patent and Trademark Office in its capacity as a Designated / Elected Office (37 CFR 1.495) has made the following determination:

- Applicant has failed to respond to the notification of MISSING REQUIREMENTS (Form PCT/DO/EO/909²²), mailed 07/05/2006 within the time period set therein.


Therefore, the above identified application failed to meet the requirements of 35 U.S.C. 371 and 37 CFR 1.495, and is ABANDONED AS TO THE UNITED STATES OF AMERICA.


DONNA S GREENE

Telephone: (703) 308-9140 EXT 222

PART 1 - ATTORNEY/APPLICANT COPY

FORM PCT/DO/EO/909 (371 Abandonment Notice)





LAP13 Rec'd PCT/PTO 04 DEC 2006

Attorney Docket No. 46483-0001-00-US (P2942)

Re: Patent Application of John D. LAMBRIS

Appl. No.: 10/528,496 (I.A. PCT/US03/29653)

Filed: I.A. 22 Sept 2003 (22.09.2003)

For: COMPSTATIN ANALOGS WITH IMPROVED ACTIVITY

The U.S. Patent Office acknowledges and has stamped hereon the date of receipt of the attached paper(s):

- (1) Amendment/Response to Notification of Comply with Requirements for Patent Applications Containing Nucleotide and/or Amino Acid Sequence Disclosures
- (2) copy of 371 Formalities Letter; (3) Written (on paper) Sequence Listing;
- (4) CRF (diskette) of Sequence Listing (5) Check for \$1020 EXT of Time (3 mos)

Certificate of Mailing § 1.10: December 4, 2006

EXPRESS LABEL NO.:

EV299884146US

Attorney Docket No. 46483-0001-00-US (P2942)
 Re: Patent Application of John D. LAMBRIS
 Appl. No.: 10/528,496 (I.A. PCT/US03/29653)
 Filed: I.A. 22 Sept 2003 (22.09.2003)
 For: COMSTATIN ANALOGS WITH IMPROVED ACTIVITY
 The U.S. Patent Office acknowledges and has stamped hereon the date of receipt of the attached paper(s):

- (1) Amendment/Response to Notification of Comply with Requirements for Patent Applications Containing Nucleotide and/or Amino Acid Sequence Disclosures
- (2) copy of 371 Formalities Letter; (3) Written (on paper) Sequence Listing;
- (4) CRF (diskette) of Sequence Listing (5) Check for \$1020 EXT of Time (3 mos)

Certificate of Mailing § 1.10: December 4, 2006

EXPRESS LABEL NO.:

EV299884146US

Customer Copy
 Label 11-F June 2002



UNITED STATES POSTAL SERVICE®

Post Office To Addressee

ORIGIN (POSTAL USE ONLY)			DELIVERY (POSTAL USE ONLY)		
PO ZIP Code 19104	Day of Delivery <input type="checkbox"/> Next <input checked="" type="checkbox"/> Second	Flat Rate Envelope <input type="checkbox"/>	Delivery Attempt Mo. Day 12 4	Time <input type="checkbox"/> AM <input checked="" type="checkbox"/> PM	Employee Signature DEC 04 2006
Date In Mo. Day Year 12 4 2006	<input checked="" type="checkbox"/> 12 Noon <input type="checkbox"/> 3 PM	Postage \$ 14.40	Delivery Attempt Mo. Day 12 4	<input type="checkbox"/> AM <input checked="" type="checkbox"/> PM	Employee Signature
Time In <input type="checkbox"/> AM <input checked="" type="checkbox"/> PM	Military <input type="checkbox"/> 2nd Day <input type="checkbox"/> 3rd Day	Return Receipt Fee	Delivery Date Mo. Day 12 4	<input type="checkbox"/> AM <input checked="" type="checkbox"/> PM	Employee Signature
Weight lbs. 4.30	Int'l Alpha Country Code	COD Fee	<input type="checkbox"/> WAIVER OF SIGNATURE (Delivery of this item is made without obtaining signature from addressee or addressee's agent. If delivery employee judges that article can be left in secure location and authorize that delivery employee signature constitutes valid proof of delivery.) <input type="checkbox"/> NO DELIVERY (Workday) <input type="checkbox"/> (Holiday)		
No Delivery <input type="checkbox"/> Weekend <input type="checkbox"/> Holiday	Acceptance Clerk Initials	Insurance Fee	Total Postage & Fees \$ 14.40		
CUSTOMER USE ONLY			CUSTOMER USE ONLY		
METHOD OF PAYMENT: Express Mail Corporate Acct. No. X192628			Federal Agency Acct. No. or Postal Service Acct. No.		
229798 (46483-0001-00-US)			229798 (46483-0001-00-US)		
FROM: (PLEASE PRINT) F.K. Spina			TO: (PLEASE PRINT) MAIL STOP PCT COMMISSIONER FOR PATENTS PO BOX 1450 ALEXANDRIA VA 22313-1450		
PHONE () ORINKER, BIDDLE & REATH LLP 1 LUGAN SQ FL 24 PHILADELPHIA PA 19103-6996			PHONE () ATTN: DO/EO/US		

PRESS HARD.
 You are making 3 copies.

FOR PICKUP OR TRACKING CALL 1-800-222-1811 www.usps.com



ORIGINAL DOCUMENT PRINTED ON CHEMICAL REACTIVE PAPER WITH MICROPRINTED BORDER

DB&R DRINKER BIDDLE & REATH-LLP
 18TH & CHERRY STREETS
 PHILADELPHIA, PA 19103-6996

BROWN BROTHERS HARRIMAN &
 PRIVATE BANKERS
 1531 WALNUT STREET
 PHILADELPHIA, PA

DATE
12/04/06

PAY ONE THOUSAND TWENTY AND 00/100 Dollars

TO THE ORDER OF
 COMMISSIONER FOR PATENTS

VOID AFTER 6 MONTH

THIS DOCUMENT CONTAINS HEAT SENSITIVE INK. TOUCH OR PRESS WHERE THE IMAGE DISAPPEARS

11 105715 0260048021 348558 811

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE
ACTING AS THE DESIGNATED/ELECTED OFFICE

In re: Patent application of John D. LAMBRIS

U.S. Appl. No. 10/528,496

I.A. Appl. No.: PCT/US03/29653

I.A. Filing Date: 22 September 2003 (22.09.2003)

Confirmation No.: 4405

For: COMPSTATIN ANALOGS WITH
IMPROVED ACTIVITY


Mail Stop PCT
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

**AMENDMENT AND RESPONSE TO NOTIFICATION TO COMPLY WITH
REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING
NUCLEOTIDE AND/OR AMINO ACID SEQUENCE DISCLOSURES**

This Amendment and Response to the NOTIFICATION TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE AND/OR AMINO ACID SEQUENCE DISCLOSURES mailed on July 5, 2006 is being filed within the third month after expiration of the shortened statutory period set in the Notification. A separate Petition for Extension of Time under 37 CFR §1.136(a) and appropriate fee, which resets the due date for response to December 5, 2006, accompany this response. Authorization is hereby provided to charge any additional fee associated with this response or to credit any over-payment to Deposit Account No. 50-0573..

In response to the Notification, the following are enclosed herewith:

- (1) copy of the aforesaid Notification;
- (2) diskette containing an initial computer readable form of the Sequence Listing; and
- (3) written (on paper) copy of the Sequence Listing.

CERTIFICATE OF MAILING UNDER 37 C.F.R. 1.10	
EXPRESS MAIL Mailing Label Number:	EV299884146US
Date of Deposit:	December 4, 2006
I hereby certify that this correspondence, along with any paper referred to as being attached or enclosed, and/or fee, is being deposited with the United States Postal Service, "EXPRESS MAIL-POST OFFICE TO ADDRESSEE" service under 37 C.F.R. 1.10, on the date indicated above, and addressed to: Mail Stop PCT, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450	
	
Signature of person mailing paper	
KAREN M. SPINA	
Type or print name of person	

Amendments to the Specification:

Please insert the enclosed Sequence Listing into the specification.

REMARKS

A Sequence Listing has been inserted into the application in written (on paper) form.
A computer readable form of the Sequence Listing is also enclosed herewith.

**STATEMENT TO SUPPORT FILING AND SUBMISSION
IN ACCORDANCE WITH 37 C.F.R. §§1.821-1.825**

I hereby state that the sequence listing information recorded in computer readable form submitted herewith is identical to the written (on paper) sequence listing submitted herewith. The submission includes no new matter.

Respectfully submitted,

JOHN D. LAMBRIS

BY 

JANET E. REED

Registration No. 36,252

Drinker Biddle & Reath LLP

One Logan Square

18th and Cherry Streets


Philadelphia, PA 19103-6996

TEL: (215) 988-3111

FAX: (215) 988-2757

Attorney for Applicant

Under the paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

PETITION FOR EXTENSION OF TIME UNDER 37 CFR 1.136(a) FY 2006 <i>(Fees pursuant to the Consolidated Appropriations Act, 2005 (H.R. 4818).)</i>		Docket Number (Optional) 46483-0001-00-US (P2942) (formerly UPN-4470)	
Application Number 10/528,496 (I.A.PCT/US03/29653)		Filed I.A. 22 SEPTEMBER 2003)	
For COMPSTATIN ANALOGS WITH IMPROVED ACTIVITY			
Art Unit n/a		Examiner n/a	
This is a request under the provisions of 37 CFR 1.136(a) to extend the period for filing a reply in the above identified application.			
The requested extension and fee are as follows (check time period desired and enter the appropriate fee below):			
	<u>Fee</u>	<u>Small Entity Fee</u>	
<input type="checkbox"/> One month (37 CFR 1.17(a)(1))	\$120	\$60	\$ _____
<input type="checkbox"/> Two months (37 CFR 1.17(a)(2))	\$450	\$225	\$ _____
<input checked="" type="checkbox"/> Three months (37 CFR 1.17(a)(3))	\$1020	\$510	\$ <u>1020</u>
<input type="checkbox"/> Four months (37 CFR 1.17(a)(4))	\$1590	\$795	\$ _____
<input type="checkbox"/> Five months (37 CFR 1.17(a)(5))	\$2160	\$1080	\$ _____
<input type="checkbox"/> Applicant claims small entity status. See 37 CFR 1.27.			
<input checked="" type="checkbox"/> A check in the amount of the fee is enclosed.			
<input type="checkbox"/> Payment by credit card. Form PTO-2038 is attached.			
<input type="checkbox"/> The Director has already been authorized to charge fees in this application to a Deposit Account.			
<input checked="" type="checkbox"/> The Director is hereby authorized to charge any fees which may be required, or credit any overpayment, to Deposit Account Number <u>50-0573</u> . I have enclosed a duplicate copy of this sheet.			
WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.			
I am the <input type="checkbox"/> applicant/inventor.			
<input type="checkbox"/> assignee of record of the entire interest. See 37 CFR 3.71. Statement under 37 CFR 3.73(b) is enclosed (Form PTO/SB/96).			
<input checked="" type="checkbox"/> attorney or agent of record. Registration Number <u>36,252</u>			
<input type="checkbox"/> attorney or agent under 37 CFR 1.34. Registration number if acting under 37 CFR 1.34 _____			
 _____ Signature		<u>December 4, 2006</u> _____ Date	
<u>JANET E. REED</u> _____ Typed or printed name		<u>(215) 988-3338</u> _____ Telephone Number	
NOTE: Signatures of all the inventors or assignees of record of the entire interest or their representative(s) are required. Submit multiple forms if more than one signature is required, see below.			
<input checked="" type="checkbox"/> Total of <u>1</u> forms are submitted.		CUSTOMER NO. 23973	

This collection of information is required by 37 CFR 1.136(a). The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to take 6 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

P2942 US Listing_ST25.txt
SEQUENCE LISTING

<110> Lambris, John D.
<120> Compstatin Analogs with Improved Activity
<130> 46483-0001-00-US (P2942)
<140> US 10/521,496
<141> 2005-03-18
<150> PCT/US03/29653
<151> 2003-09-22
<150> US 60/412,220
<151> 2002-09-20
<160> 15
<170> PatentIn version 3.4
<210> 1
<211> 13
<212> PRT
<213> Artificial sequence
<220>
<223> synthetic sequence
<400> 1

Ile Cys Val Val Gln Asp Trp Gly His His Arg Cys Thr
1 5 10

<210> 2
<211> 13
<212> PRT
<213> Artificial sequence
<220>
<223> synthetic sequence

<220>
<221> MOD_RES
<222> (1)..(1)
<223> ACETYLTATION

<400> 2

Ile Cys Val Val Gln Asp Trp Gly His His Arg Cys Thr
1 5 10

<210> 3
<211> 13
<212> PRT
<213> Artificial sequence
<220>
<223> synthetic sequence

<220>
 <221> MOD_RES
 <222> (1)..(1)
 <223> ACETYLATION

<400> 3

Ile Cys Val Trp Gln Asp Trp Gly Ala His Arg Cys Thr
 1 5 10

<210> 4
 <211> 13
 <212> PRT
 <213> Artificial sequence

<220>
 <223> synthetic sequence

<220>
 <221> MOD_RES
 <222> (1)..(1)
 <223> ACETYLATION,

<220>
 <221> MOD_RES
 <222> (13)..(13)
 <223> Carboxylation

<400> 4

Ile Cys Val Trp Gln Asp Trp Gly Ala His Arg Cys Thr
 1 5 10

<210> 5
 <211> 13
 <212> PRT
 <213> Artificial sequence

<220>
 <223> synthetic sequence

<220>
 <221> MOD_RES
 <222> (1)..(1)
 <223> ACETYLATION

<400> 5

Ile Cys Val Trp Gln Asp Trp Gly Ala His Arg Cys Thr
 1 5 10

<210> 6
 <211> 13
 <212> PRT
 <213> Artificial sequence

<220>

<223> synthetic sequence

<220>

<221> MOD_RES

<222> (1)..(1)

<223> ACETYLATION

<220>

<221> MOD_RES

<222> (13)..(13)

<223> D-threonine, carboxylated

<400> 6

Ile Cys Val Trp Gln Asp Trp Gly Ala His Arg Cys Thr
1 5 10

<210> 7

<211> 13

<212> PRT

<213> Artificial sequence

<220>

<223> synthetic sequence

<220>

<221> MOD_RES

<222> (1)..(1)

<223> ACETYLATION

<220>

<221> MOD_RES

<222> (4)..(4)

<223> X is 2-naphthalene

<400> 7

Ile Cys Val Xaa Gln Asp Trp Gly Ala His Arg Cys Thr
1 5 10

<210> 8

<211> 13

<212> PRT

<213> Artificial sequence

<220>

<223> synthetic sequence

<220>

<221> MOD_RES

<222> (1)..(1)

<223> ACETYLATION

<220>

<221> MOD_RES

<222> (4)..(4)

<223> X is 2-naphthalene

<220>
 <221> MOD_RES
 <222> (13)..(13)
 <223> carboxylation

<400> 8

Ile Cys Val Xaa Gln Asp Trp Gly Ala His Arg Cys Thr
 1 5 10

<210> 9
 <211> 13
 <212> PRT
 <213> Artificial sequence

<220>
 <223> synthetic sequence

<220>
 <221> MOD_RES
 <222> (1)..(1)
 <223> ACETYLTATION

<220>
 <221> MOD_RES
 <222> (4)..(4)
 <223> X is 1-naphthalene

<220>
 <221> MOD_RES
 <222> (13)..(13)
 <223> carboxylation

<400> 9

Ile Cys Val Xaa Gln Asp Trp Gly Ala His Arg Cys Thr
 1 5 10

<210> 10
 <211> 13
 <212> PRT
 <213> Artificial sequence

<220>
 <223> synthetic sequence

<220>
 <221> MOD_RES
 <222> (1)..(1)
 <223> ACETYLTATION

<220>
 <221> MOD_RES
 <222> (4)..(4)
 <223> X is 2 indanylglycine carboxylic acid

<400> 10

Ile Cys Val Xaa Gln Asp Trp Gly Ala His Arg Cys Thr
 Page 4

<210> 13
 <211> 13
 <212> PRT
 <213> Artificial sequence

<220>
 <223> synthetic sequence

<220>
 <221> MOD_RES
 <222> (1)..(1)
 <223> ACETYLATION

<220>
 <221> MOD_RES
 <222> (4)..(4)
 <223> X is benzoylphenylalanine

<220>
 <221> MOD_RES
 <222> (13)..(13)
 <223> carboxylation

<400> 13

Ile Cys Val Xaa Gln Asp Trp Gly Ala His Arg Cys Thr
 1 5 10

<210> 14
 <211> 16
 <212> PRT
 <213> Artificial sequence

<220>
 <223> synthetic sequence

<220>
 <221> MOD_RES
 <222> (16)..(16)
 <223> carboxylation

<400> 14

Gly Ile Cys Val Trp Gln Asp Trp Gly Ala His Arg Cys Thr Ala Asn
 1 5 10 15

<210> 15
 <211> 13
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> synthetic sequence

<220>
 <221> MOD_RES
 <222> (1)..(1)
 <223> X is Ile, Val, Leu, Ac-Ile, Ac-Val, Ac-Leu or a dipeptide

comprising Gly-Ile

<220>

<221> MOD_RES

<222> (4)..(4)

<223> X is Trp or a peptidic or non-peptidic analog of Trp

<220>

<221> MOD_RES

<222> (9)..(9)

<223> X is His, Ala, Phe or Trp

<220>

<221> MOD_RES


<222> (13)..(13)

<223> X is L-Thr, D-Thr, Ile, Val, Gly, or a tripeptide comprising Thr-Ala-Asn, wherein a carboxy terminal -OH of any of the L-Thr, D-Thr, Ile, Val, Gly or Asn optionally is replaced by -NH₂

<400> 15

Xaa Cys Val Xaa Gln Asp Trp Gly Xaa His Arg Cys Xaa
 1 5 10

Applicant: Lambris, John D.
File Ref.: 46406-0001-00-US (P2942)
Saved to Disk: 2006-11-29
Title: Compstatin Analogs with Improved Activity
Filing Date: 2005-03-18
Appl. No. 10/528,496
Operating Sys: Windows 5.01



02 1M
00942240
MAILED FR

FIRST CLASS MAIL

From
DrinkerBiddle&Reath
One Logan Square
18th & Cherry Streets
Philadelphia, PA 19103-6996

Mail Stop *PCT*
Commissioner for Patents
P. O. Box 1450
Alexandria, VA 22313-1450



**This Page is Inserted by IFW Indexing and Scanning
Operations and is not part of the Official Record**

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- ☒ **BLACK BORDERS**
- ☐ **IMAGE CUT OFF AT TOP, BOTTOM OR SIDES**
- ☒ **FADED TEXT OR DRAWING**
- ☐ **BLURRED OR ILLEGIBLE TEXT OR DRAWING**
- ☐ **SKEWED/SLANTED IMAGES**
- ☐ **COLOR OR BLACK AND WHITE PHOTOGRAPHS**
- ☐ **GRAY SCALE DOCUMENTS**
- ☐ **LINES OR MARKS ON ORIGINAL DOCUMENT**
- ☐ **REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY**
- ☐ **OTHER:** _____

IMAGES ARE BEST AVAILABLE COPY.

As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.